KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Capital Expenditures for 16 consecutive years, with -$24.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 173.07% year-over-year to -$24.5 million, compared with a TTM value of $10.9 million through Dec 2025, down 68.19%, and an annual FY2025 reading of $10.9 million, down 68.19% over the prior year.
  • Capital Expenditures was -$24.5 million for Q4 2025 at Alnylam Pharmaceuticals, down from $31.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $43.9 million in Q3 2022 and bottomed at -$45.2 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $3.4 million, with a median of $7.4 million recorded in 2021.
  • The sharpest move saw Capital Expenditures plummeted 200.84% in 2022, then soared 9858.26% in 2025.
  • Year by year, Capital Expenditures stood at -$40.9 million in 2021, then fell by 10.58% to -$45.2 million in 2022, then grew by 4.68% to -$43.1 million in 2023, then soared by 177.81% to $33.5 million in 2024, then crashed by 173.07% to -$24.5 million in 2025.
  • Business Quant data shows Capital Expenditures for ALNY at -$24.5 million in Q4 2025, $31.3 million in Q3 2025, and $431000.0 in Q2 2025.